Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tract creation with a 25-gauge needle for convex endobronchial ultrasound-guided core biopsy in intrapulmonary lesions adjacent to bronchi: three case reports.
Nagamine H, Nakai T, Ueda T, Nakahama K, Sawa K, Yamada K, Watanabe T, Aasai K, Kawaguchi T. Nagamine H, et al. Among authors: nakahama k. Transl Lung Cancer Res. 2023 Dec 26;12(12):2550-2557. doi: 10.21037/tlcr-23-556. Epub 2023 Dec 11. Transl Lung Cancer Res. 2023. PMID: 38205200 Free PMC article.
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Kaneda H, Sawa K, Daga H, Okada A, Nakatani Y, Atagi S, Okishio K, Tani Y, Matsumoto Y, Ogawa K, Nakahama K, Izumi M, Mitsuoka S, Kawaguchi T. Kaneda H, et al. Among authors: nakahama k. Invest New Drugs. 2021 Dec;39(6):1598-1603. doi: 10.1007/s10637-021-01147-w. Epub 2021 Jul 2. Invest New Drugs. 2021. PMID: 34215931 Clinical Trial.
Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Thorac Cancer. 2022 Aug;13(16):2309-2317. doi: 10.1111/1759-7714.14560. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808895 Free PMC article.
SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.
Nakahama K, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Transl Lung Cancer Res. 2022 Dec;11(12):2438-2451. doi: 10.21037/tlcr-22-496. Transl Lung Cancer Res. 2022. PMID: 36636414 Free PMC article.
RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
Nagamine H, Yashiro M, Yoshimoto N, Izumi M, Sugimoto A, Nakahama K, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Yamada K, Watanabe T, Aasai K, Fukumura K, Mayeda A, Kawaguchi T. Nagamine H, et al. Among authors: nakahama k. Anticancer Res. 2023 Oct;43(10):4663-4672. doi: 10.21873/anticanres.16662. Anticancer Res. 2023. PMID: 37772582
135 results